ArticleMolecular biology reports2026
Angiotensin Converting Enzyme (ACE) insertion/deletion (rs1799752) gene polymorphism and bladder cancer aggressiveness in Egyptian patients: A pilot case-control study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer (BC) is one of the most frequent malignancies of the urinary tract.
objectivesThis study aimed to investigate the association between angiotensin-converting enzyme (ACE) I/D polymorphism (rs1799752) and bladder cancer risk in Egyptian patients. DESIGN AND
methodsBladder cancer cases (n = 140) were diagnosed based on cystoscopy and confirmed by histopathological examination of biopsies. Fifty sex- and age-matched healthy individuals served as controls. Peripheral blood was used to extract the genomic DNA, and the ACE I/D (rs1799752) polymorphism was genotyped using polymerase chain reaction (PCR).
resultsGenotype frequencies were comparable between groups (II:12% vs. 11.4%, ID: 76% vs. 74%, and DD: 12% vs14.3% in control and BC patients, respectively), with no significant difference in allele or genotype distributions (co-dominant model DD vs. II: OR 1.25, 95%CI 0.34-4.63, p = 0.751). However, within the patient group, the heterozygous genotype (ID) was significantly more prevalent in high grade tumors (P = 0.0177), muscle-invasive BC (MIBC, p = 0.0042), and poor prognosis cases (high grade + MIBC, P < 0.0017). The over-dominant model (ID vs. II + DD) showed a strong association with poor prognosis (OR = 4.8, 95%CI 1.96-11.78, p < 0.001). A trend toward higher ID frequency that did not reach statistical significance was observed in advanced stages (T3/T4, p = 0.058).
conclusionThe ID genotype is strongly linked to the carcinogenesis of BC and with the poor prognosis, indicating its possible role as a predictive biomarker for risk assessment and progression in this population.
Indexed as
Identifiers
42377753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.